Raphamin

Phase 3Small molecule

MMateria Medica Holding

Raphamin is one of 115 small molecule programs targeting Efficacy and Safety. It is currently in Phase 3.

Indications

Total Trials

Active Trials

114

Competitors

Pipeline

Status by Indication[3][1]

Indication

Efficacy and SafetyCompleted

BronchitisRecruiting

SinusitisRecruiting

CystitisActive, not recruiting

Efficacy and SafetyPhase 3

Completed

BronchitisPhase 3

Recruiting

SinusitisPhase 3

Recruiting

CystitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

242 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

Savaysa

Daiichi Sankyo

Phase 3

3 2

Rilutek

AAzurity Pharmaceuticals

Phase 3

3 3

Kineret

SSwedish Orphan Biovitrum

Phase 3

2 4

BESREMI

PPharmaEssentia

Phase 3

2 5

Romiplostim N01

Qilu Pharmaceutical Co., Ltd.

Phase 3

1 6

VAY736

Novartis

Phase 3

2 7

Raphamin

MMateria Medica Holding

Phase 3

2 8

Zvs101e

CChigenovo Co., Ltd

Phase 3

1 9

Ralinepag

United Therapeutics

Phase 3

2 10

AVTX-803

AAUG Therapeutics

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Cystitis

NCT06284265

Q4 2027

Phase 3Recruiting

Sinusitis

NCT06901297

Phase 3Recruiting

Efficacy and Safety

NCT06715891

Q4 2028

Phase 3Recruiting

Bronchitis

NCT07650227

Clinical

Trials by Indication[1]

Efficacy and Safety2 trials

Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old

Completed·MMateria Medica Holding·Phase 3·NCT04918771·435 enrolled

Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of ARVI in Children Aged 3-12 Years

Recruiting·MMateria Medica Holding·Phase 3·NCT06715891·374 enrolled

Coronavirus Disease 20191 trial

Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients

Completed·MMateria Medica Holding·Phase 3·NCT05364671·771 enrolled

Sinusitis1 trial

The Efficacy and Safety of Raphamin in the Treatment of Acute Rhinosinusitis in Adult Patients

Recruiting·MMateria Medica Holding·Phase 3·NCT06901297·552 enrolled

Pneumonia1 trial

Clinical Trial of the Efficacy and Safety of Raphamin in Combined Treatment of Community-acquired Pneumonia

Completed·MMateria Medica Holding·Phase 3·NCT06263881·370 enrolled

Cystitis1 trial

Clinical Trial of the Efficacy and Safety of Raphamin in Prevention of Recurrences of Chronic Bacterial Cystitis

Active, not recruiting·MMateria Medica Holding·Phase 3·NCT06284265·415 enrolled

1 more indication

Bronchitis1 trial

Multicenter, Double Blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of Acute Bronchitis in Adult Patients

Recruiting·MMateria Medica Holding·Phase 3·NCT07650227·308 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Raphamin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Raphamin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Raphamin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Materia Medica Holding company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMateria Medica Holding

Raphamin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q4 2028

Trials by Indication[1]

Efficacy and Safety2 trials

Coronavirus Disease 20191 trial

Sinusitis1 trial

Pneumonia1 trial

Cystitis1 trial

Bronchitis1 trial

References

Drug Info

Quick Facts

Related News